研究等業績 - その他 - 三浦　昌朋

Determination of Plasma Concentrations of Imatinib by a Novel Automated Analyzer Based on High-Performance Liquid Chromatography

Fukushi Y.

Yakugaku Zasshi ( Yakugaku Zasshi )  143 ( 11 ) 963 - 969   2023年

<p>LM1010 HPLC is an emerging automated method designed for use in clinical settings. The aim of this study was to compare the analytical performance of LM1010 with the performance of traditional HPLC and LC-MS/MS in the measurement of plasma concentrations of imatinib. Seventy-eight plasma samples from 20 patients (14 men and 6 women) were collected. Plasma concentrations of imatinib in samples from the same patient were analyzed simultaneously using LM1010, HPLC and LC-MS/MS (LSI Medience Corporation). Strong correlations were seen in pairwise comparisons of results from the LM1010 and HPLC methods, the LM1010 and LC-MS/MS methods, and the LC-MS/MS and HPLC methods (Spearman’s <i>r</i>=0.936, 0.906, and 0.953, respectively); however, the results from the LC-MS/MS method showed a positive proportional bias in comparison with the results from the LM1010 and HPLC methods, according to Deming analyses (slope=1.064 and 1.105, respectively). In Bland–Altman analyses, the LC-MS/MS method showed a positive mean bias of 98.6 and 112 ng/mL in comparison with the LM1010 and HPLC methods, respectively. Notably, results obtained using the LM1010 method were comparable to those using the HPLC method (positive mean bias=13.6 ng/mL; 95% confidence interval, −7.9–35.1 ng/mL). Biochemical parameters or drugs taken concomitantly with imatinib were not found to affect the bias of the LM1010 method. The LM1010 method can be applied to routine therapeutic drug monitoring of imatinib.</p>

DOI PubMed CiNii Research

Circulating IL-6 and not its circulating signaling components sIL-6R and sgp130 demonstrate clinical significance in NSCLC patients treated with immune checkpoint inhibitors

Nakahara Y.

Frontiers in Cell and Developmental Biology ( Frontiers in Cell and Developmental Biology )  11   2023年

DOI

A Multi-institutional Study to Diagnose the Risk of Lymph Node Metastasis Using a CRP Genetic Polymorphism Test Kit in pT1, cN0 Thoracic Esophageal Squamous Cell Carcinoma

Motoyama S.

Anticancer Research ( Anticancer Research )  42 ( 12 ) 6105 - 6112   2022年12月

DOI

Effects of NR1I2 and ABCB1 Genetic Polymorphisms on Everolimus Pharmacokinetics in Japanese Renal Transplant Patients

Yagishita H.

International Journal of Molecular Sciences ( International Journal of Molecular Sciences )  23 ( 19 )   2022年10月

DOI

Safe administration and pharmacokinetic monitoring of crushed venetoclax tablets with posaconazole and clarithromycin via percutaneous endoscopic gastrostomy tube in a patient with acute myeloid leukemia

Sato H.

Cancer Chemotherapy and Pharmacology ( Cancer Chemotherapy and Pharmacology )  90 ( 3 ) 279 - 284   2022年09月

DOI

次世代の薬剤師を支えるTDMエビデンスの創出

尾田 一貴, 三浦 昌朋, 榎屋 友幸

日本医療薬学会年会講演要旨集 ( 一般社団法人 日本医療薬学会 )  32 ( 0 ) 288 - 293   2022年09月

DOI CiNii Research

Relationship between achievement of major molecular response or deep molecular response and nilotinib plasma concentration in patients with chronic myeloid leukemia receiving first-line nilotinib therapy

Fukuda N.

Cancer Chemotherapy and Pharmacology ( Cancer Chemotherapy and Pharmacology )  89 ( 5 ) 609 - 616   2022年05月

DOI

Associations Between Plasma Concentrations of Lenvatinib and Angiopoietin and Clinical Responses to Lenvatinib Therapy in Japanese Patients With Thyroid Cancer

Kumagai M.

Cancer Diagnosis and Prognosis ( Cancer Diagnosis and Prognosis )  2 ( 3 ) 336 - 344   2022年

DOI

Effects of CYP3A4/5 and ABC transporter polymorphisms on osimertinib plasma concentrations in Japanese patients with non-small cell lung cancer

Yokota H.

Investigational New Drugs ( Investigational New Drugs )  40 ( 6 ) 1254 - 1262   2022年

DOI CiNii Research

Impact of trough abiraterone level on adverse events in patients with prostate cancer treated with abiraterone acetate

Takahashi Y.

European Journal of Clinical Pharmacology ( European Journal of Clinical Pharmacology )  79 ( 1 ) 89 - 98   2022年

DOI

Effects of ABCB1 polymorphisms on the transport of ponatinib into the cerebrospinal fluid in Japanese Philadelphia chromosome-positive acute lymphoblastic leukaemia patients

Fukushi Y.

British Journal of Clinical Pharmacology ( British Journal of Clinical Pharmacology )  89 ( 5 ) 1695 - 1700   2022年

DOI

Effects of SLC22A2 808G&gt;T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy

Abumiya M.

Scientific Reports ( Scientific Reports )  11 ( 1 )   2021年12月

DOI

Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial

Murai K.

The Lancet Haematology ( The Lancet Haematology )  8 ( 12 ) e902 - e911   2021年12月

DOI

Regulatory t cell as a biomarker of treatment-free remission in patients with chronic myeloid leukemia

Fujioka Y.

Cancers ( Cancers )  13 ( 23 )   2021年12月

DOI

Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph + ALL

Kawano N.

International Journal of Hematology ( International Journal of Hematology )  114 ( 4 ) 509 - 516   2021年10月

DOI

Relationship between plasma concentrations of afatinib and the onset of diarrhea in patients with non-small cell lung cancer

Yokota H.

Biology ( Biology )  10 ( 10 )   2021年10月

DOI

TDMエビデンスの創出・進化に向けたあくなき挑戦

尾田 一貴, 三浦 昌朋, 榎屋 友幸

日本医療薬学会年会講演要旨集 ( 一般社団法人 日本医療薬学会 )  31 ( 0 ) S27 - S27   2021年10月

DOI CiNii Research

Evaluation of the plasma concentration of ponatinib in a chronic myeloid leukaemia patient with ponatinib intolerance

Abumiya M.

Journal of Clinical Pharmacy and Therapeutics ( Journal of Clinical Pharmacy and Therapeutics )  46 ( 1 ) 219 - 222   2021年02月

DOI

Effects of SLC31A1 and ATP7B polymorphisms on platinum resistance in patients with esophageal squamous cell carcinoma receiving neoadjuvant chemoradiotherapy

Fujita K.

Medical Oncology ( Medical Oncology )  38 ( 1 )   2021年01月

DOI

The BCRP inhibitor febuxostat enhances the effect of nilotinib by regulation of intracellular concentration

Ito F.

International Journal of Hematology ( International Journal of Hematology )  113 ( 1 ) 100 - 105   2021年01月

DOI